+ Formulaic incentive plan
The specific financial center may change within a reasonable commuting distance; weekend or extended-hours scheduling may be required.
Bank of America provides a full range of financial services to individuals, small businesses, and large corporations, including banking, investing, asset management, and risk management products. Customers access services via branches, online and mobile banking, and advisory and trading capabilities across consumer banking, wealth management, corporate and investment banking. Its breadth, scale, and global reach enable cross-service solutions and large-scale operations that few peers match. Its goal is to be a trusted, full-service financial partner helping customers manage money, grow assets, and navigate risk.
Company Size
10,001+
Company Stage
IPO
Headquarters
Charlotte, North Carolina
Founded
1904
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Paid Vacation
Paid Sick Leave
Flexible Work Hours
Remote Work Options
Professional Development Budget
Conference Attendance Budget
Stepan Company has secured a new $500 million five-year credit agreement, replacing its previous $450 million facility and boosting liquidity by $50 million. The specialty chemicals maker announced the deal on 25 September 2026. The new package comprises a $350 million multicurrency revolving credit facility and a $150 million delayed draw term loan, both maturing in September 2031. An expansion option allows Stepan to increase total capacity to $750 million if needed. Interest rates are tied to the company's net leverage ratio, with spreads ranging from 1.125% to 1.625% above benchmark rates. JPMorgan Chase Bank serves as administrative agent, with Bank of America as syndication agent. The agreement includes standard financial covenants and will finance working capital, acquisitions, capital expenditure, and general corporate purposes.
Bank of America has launched Payments Insights, a new feature within its AI-powered CashPro Data Intelligence suite. The capability provides corporate and commercial clients with actionable intelligence on payment efficiency, cross-border flows and working-capital performance for their US accounts. The tool uses proprietary peer benchmarking and dynamic visualisations to help treasury teams identify trends and areas requiring attention. It was developed with direct client input, including feedback from the bank's CashPro Boards. CashPro facilitated 213 million payments in the first half of 2026, representing a 10% year-on-year increase. The new insights aim to help clients optimise payment methods, cross-border transactions and currency usage. Jennifer Sanctis, head of CashPro Personalised Technologies, said the tool helps finance teams "cut through complexity and focus on the decisions that matter most".
Bank of America Securities cut its price target on Carnival from $42 to $38 ahead of the cruise operator's third-quarter earnings report on 29 September. Analyst Andrew Didora cited surging fuel costs as the primary concern, not weakening demand. Brent oil has gained 30% amid increased Middle East tensions. Carnival is the only unhedged cruise operator among its rivals, making it particularly vulnerable. The company reported fuel costs were up roughly 30% in the second quarter, resulting in a $73 million negative impact. Despite robust demand and record quarterly revenue of $6.7 billion, fuel remains Carnival's biggest problem. Customer deposits hit a record $9 billion in the second quarter. Combined Bank of America credit and debit card spending on cruise lines jumped to the mid-teens year over year in July and August.
An announcement from Essex Property ( ($ESS) ) is now available. On September 24, 2026, Essex Property Trust, Inc., through its operating partnership Essex Portfoli...
Bank of America met with Merck's chief medical officer and maintained its Buy rating with a $166 price target, citing confidence in the drugmaker's pipeline. The meeting focused on sacituzumab tirumotecan, an antibody-drug conjugate being tested in lung cancer, with results expected 25 October at the European Society for Medical Oncology Congress. Merck's Keytruda generated $31.7 billion in 2025 sales but faces US patent expiration starting in 2028. Management claims newer drugs carry over $70 billion in annual revenue potential by the mid-2030s. The chief medical officer dismissed concerns about a failed June trial with rival Gilead Sciences, noting different patient populations. BofA analysts believe pipeline data will drive the stock's next gains, though the $166 target offers modest upside from current levels.